In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer
- 3 June 2011
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 132 (2) , 463-470
Abstract
HER2 overexpression/amplification is linked with poor prognosis in early breast cancer. Co-expression of HER2 and HER3 is associated with endocrine and chemotherapy resistance, driven not simply by expression but by signalling via HER2:HER3 or HER2:HER2 dimers. Proximity ligation assays (PLAs) detect protein–protein complexes at a single-molecule level and allow study of signalling pathways in situ. A cohort of 100 tumours was analyzed by PLA, IHC and FISH. HER complexes were analyzed by PLA in a further 321 tumours from the BR9601 trial comparing cyclophosphamide, methotrexate and fluorouracil (CMF) with epirubicin followed by CMF (epi-CMF). The relationships between HER dimer expression and RFS and OS were investigated, and multivariate regression analysis identified factors influencing patient prognosis. PLA successfully and reproducibly detected HER2:HER2 and HER2:HER3 protein complexes in vivo. A significant association (P < 0.00001) was identified between HER2 homodimerization and HER2 gene amplification. Following a minimum p value approach high levels of HER2:HER2 dimers were significantly associated with reduced relapse-free (RFS; hazard ratio = 1.72, 95% confidence interval 1.15–2.56, P = 0.008) and overall survival (OS HR = 1.69 95% CI = 1.09–2.62, P = 0.019). Similarly, high levels of HER2:HER3 dimers were associated with reduced RFS (HR = 2.18, 95% CI = 1.46–3.26, P = 0.00016) and OS (HR = 2.21, 95% CI = 1.41–3.47, P = 0.001). This study demonstrates that in situ detection of HER2 and HER2:3 protein:protein complexes can be performed robustly and reproducibly in clinical specimens, provides novel prognostic information and opens a significant novel opportunity to probe the clinical impact of cellular signalling processes.Keywords
This publication has 25 references indexed in Scilit:
- In situ quantification of HER2–protein tyrosine kinase 6 (PTK6) protein–protein complexes in paraffin sections from breast cancer tissuesBritish Journal of Cancer, 2010
- Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISHDiagnostic Molecular Pathology, 2009
- Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assayMethods, 2008
- Multiplexed protein detection by proximity ligation for cancer biomarker validationNature Methods, 2007
- Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast CancerNew England Journal of Medicine, 2006
- Direct observation of individual endogenous protein complexes in situ by proximity ligationNature Methods, 2006
- Observer variation in immunohistochemical analysis of protein expression, time for a change?Histopathology, 2006
- Androgen receptor gene amplification and protein expression in hormone refractory prostate cancerBritish Journal of Cancer, 2003
- Expression of the HER1–4 family of receptor tyrosine kinases in breast cancerThe Journal of Pathology, 2003
- Protein detection using proximity-dependent DNA ligation assaysNature Biotechnology, 2002